iDOVE
Durability of Vaccine Efficacy Against SARS-CoV-2 Infection
Implements a nonparametric maximum likelihood method for assessing potentially time-varying vaccine efficacy (VE) against SARS-CoV-2 infection under staggered enrollment and time-varying community transmission, allowing crossover of placebo volunteers to the vaccine arm. Lin, D. Y., Gu, Y., Zeng, D., Janes, H. E., and Gilbert, P. B. (2021) <doi:10.1093/cid/ciab630>.
Versions across snapshots
| Version | Repository | File | Size |
|---|---|---|---|
1.5 |
rolling source/ R- | iDOVE_1.5.tar.gz |
447.7 KiB |
1.5 |
rolling linux/jammy R-4.5 | iDOVE_1.5.tar.gz |
557.3 KiB |
1.5 |
rolling linux/noble R-4.5 | iDOVE_1.5.tar.gz |
565.1 KiB |
1.5 |
latest source/ R- | iDOVE_1.5.tar.gz |
447.7 KiB |
1.5 |
latest linux/jammy R-4.5 | iDOVE_1.5.tar.gz |
557.3 KiB |
1.5 |
latest linux/noble R-4.5 | iDOVE_1.5.tar.gz |
565.1 KiB |
1.5 |
2026-04-26 source/ R- | iDOVE_1.5.tar.gz |
447.7 KiB |
1.5 |
2026-04-23 source/ R- | iDOVE_1.5.tar.gz |
447.7 KiB |
1.5 |
2026-04-09 windows/windows R-4.5 | iDOVE_1.5.zip |
971.7 KiB |
1.5 |
2025-04-20 source/ R- | iDOVE_1.5.tar.gz |
447.7 KiB |